U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07562347) titled 'Clinical Experience and Real-world Safety and Effectiveness of Envafolimab: Patient Access Program' on April 24.
Brief Summary: Envafolimab is a novel PD-L1 inhibitor administered via subcutaneous (SC) injection - notably the first such checkpoint inhibitor approved for use worldwide.[1] In November 2021, Envafolimab received its first approval in China for adults with advanced microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) solid tumors that have progressed after standard therapies. This SC route offers substantial practical advantages, significantly shortening treatment administration time and sparing patie...